Laurence J. Blumberg

Cambridge Heart, Inc. engages in the development and commercialization of products for the non-invasive diagnosis of cardiac disease. The company was founded by Jeffrey M. Arnold and Jordan S. Davis on January 16, 1990 and is headquartered in Tewksbury, MA.

AFB Fund LLC provides fund and sub-fund services. It offers general, designated, restricted and auxiliary fund services. The company is headquartered in Tenafly, NJ.

Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA.

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

Blumberg Capital Management LLC is a hedge fund manager located in New York City.

Alliance Capital Corp. provides equipment financing and leasing services. It offers capital, operating, TRAC lease services. The company was founded in 1995 and is headquartered in Minneapolis, MN.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.